NO306158B1 - Anvendelse av heterosykliske benzensulfonyliminderivater som inhibitorer av IL-1-virkning - Google Patents

Anvendelse av heterosykliske benzensulfonyliminderivater som inhibitorer av IL-1-virkning

Info

Publication number
NO306158B1
NO306158B1 NO962156A NO962156A NO306158B1 NO 306158 B1 NO306158 B1 NO 306158B1 NO 962156 A NO962156 A NO 962156A NO 962156 A NO962156 A NO 962156A NO 306158 B1 NO306158 B1 NO 306158B1
Authority
NO
Norway
Prior art keywords
inhibitors
pct
activity
sec
heterocyclic
Prior art date
Application number
NO962156A
Other languages
English (en)
Norwegian (no)
Other versions
NO962156L (no
NO962156D0 (no
Inventor
George Ku
Boyd Lynn Harrison
David Martin Stemerick
Original Assignee
Merrell Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc
Publication of NO962156L publication Critical patent/NO962156L/no
Publication of NO962156D0 publication Critical patent/NO962156D0/no
Publication of NO306158B1 publication Critical patent/NO306158B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Pyrane Compounds (AREA)
NO962156A 1993-11-29 1996-05-28 Anvendelse av heterosykliske benzensulfonyliminderivater som inhibitorer av IL-1-virkning NO306158B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15866193A 1993-11-29 1993-11-29
PCT/US1994/012575 WO1995014670A1 (en) 1993-11-29 1994-11-03 Heterocyclic benzenesulfonylimine derivatives as inhibitors of il-1 action

Publications (3)

Publication Number Publication Date
NO962156L NO962156L (no) 1996-05-28
NO962156D0 NO962156D0 (no) 1996-05-28
NO306158B1 true NO306158B1 (no) 1999-09-27

Family

ID=22569128

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962156A NO306158B1 (no) 1993-11-29 1996-05-28 Anvendelse av heterosykliske benzensulfonyliminderivater som inhibitorer av IL-1-virkning

Country Status (20)

Country Link
US (1) US5668143A (hu)
EP (1) EP0731792B1 (hu)
JP (1) JP3612073B2 (hu)
KR (1) KR100351884B1 (hu)
CN (1) CN1045596C (hu)
AT (1) ATE176225T1 (hu)
AU (1) AU682736B2 (hu)
CA (1) CA2177146C (hu)
DE (1) DE69416324T2 (hu)
DK (1) DK0731792T3 (hu)
ES (1) ES2129794T3 (hu)
FI (1) FI113368B (hu)
GR (1) GR3029485T3 (hu)
HU (1) HU222819B1 (hu)
IL (1) IL111774A (hu)
NO (1) NO306158B1 (hu)
NZ (1) NZ276570A (hu)
TW (1) TW281671B (hu)
WO (1) WO1995014670A1 (hu)
ZA (1) ZA949301B (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2131297T3 (es) * 1993-11-29 1999-07-16 Merrell Pharma Inc Nuevos derivados de bencenosulfonilamina como inhibidores de la accion il-1.
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
EP1406621A2 (en) * 2001-06-26 2004-04-14 Beth Israel Deaconess Medical Center Compositions and methods for inhibiting platelet activation and thrombosis
KR100687522B1 (ko) * 2005-05-28 2007-02-27 한국화학연구원 2,2-디메틸-3-에스테르-4-알콕시-6-알킬 아미노벤조피란 유도체를 유효성분으로 함유하는 pge2 활성에 관련된 염증질환 치료제
PT2771180T (pt) 2011-10-28 2016-08-05 Iseli Alfred Método para fabricar estruturas de cartão ultraleves que possuem uma estabilidade mecânica substancial

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US3996934A (en) * 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3921636A (en) * 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
US4031894A (en) * 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
GB8719102D0 (en) * 1987-08-12 1987-09-16 Merck Sharp & Dohme Therapeutic agents
WO1992015565A1 (en) * 1991-02-27 1992-09-17 Merrell Dow Pharmaceuticals Inc. Nmda antagonists
JPH05331169A (ja) * 1992-05-26 1993-12-14 Sumitomo Pharmaceut Co Ltd ベンゾナフチリジン誘導体

Also Published As

Publication number Publication date
WO1995014670A1 (en) 1995-06-01
EP0731792B1 (en) 1999-01-27
FI962236A (fi) 1996-05-28
DK0731792T3 (da) 1999-09-13
CA2177146C (en) 1999-07-06
DE69416324D1 (de) 1999-03-11
IL111774A (en) 1999-11-30
CN1136312A (zh) 1996-11-20
CN1045596C (zh) 1999-10-13
TW281671B (hu) 1996-07-21
IL111774A0 (en) 1995-01-24
ZA949301B (en) 1995-08-07
KR100351884B1 (ko) 2002-12-31
JP3612073B2 (ja) 2005-01-19
FI113368B (fi) 2004-04-15
US5668143A (en) 1997-09-16
HU222819B1 (hu) 2003-11-28
DE69416324T2 (de) 1999-06-10
NZ276570A (en) 2001-02-23
GR3029485T3 (en) 1999-05-28
JPH09506344A (ja) 1997-06-24
AU682736B2 (en) 1997-10-16
HU9601434D0 (en) 1996-07-29
ES2129794T3 (es) 1999-06-16
FI962236A0 (fi) 1996-05-28
AU1086895A (en) 1995-06-13
EP0731792A1 (en) 1996-09-18
NO962156L (no) 1996-05-28
NO962156D0 (no) 1996-05-28
HUT76272A (en) 1997-07-28
ATE176225T1 (de) 1999-02-15
CA2177146A1 (en) 1995-06-01

Similar Documents

Publication Publication Date Title
DK0730587T3 (da) 3-phenyl-2-isoxazoliner som anti-inflammatoriske midler
DE69115280D1 (de) Indolderivate, die die leukotrienbiosynthese hemmen.
ATE210971T1 (de) Polyol-zusammensetzung
DK0731791T3 (da) Benzensulfonyliminderivater som inhibitorer af IL-1-virkning
DK0554247T3 (da) Neurobeskyttende indolon og beslægtede derivater
NO962156L (no) Heterosykliske benzensulfonyliminderivater som inhibitorer av IL-1-virkning
FI973221A (fi) 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
DE69418035D1 (de) Hiv-proteaseinhibitoren
NO944809L (no) Biologisk aktive ureidoderivater som er nyttig i behandling av lentivirus-indusert sykdom

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN MAY 2002